Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PCVX – Vaxcyte, Inc.

Vaxcyte, Inc.
PCVX
$36.31
Name : Vaxcyte, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,684,135,424.00
EPSttm : -3.99
finviz dynamic chart for PCVX
Vaxcyte, Inc.
$36.31
4.34%
$1.51

Float Short %

10.79

Margin Of Safety %

Put/Call OI Ratio

0.45

EPS Next Q Diff

-0.17

EPS Last/This Y

-0.89

EPS This/Next Y

-0.52

Price

34.8

Target Price

125.75

Analyst Recom

1

Performance Q

-53.48

Relative Volume

0.44

Beta

1.2

Ticker: PCVX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07PCVX290.355.4311724
2025-05-08PCVX31.410.360.1411809
2025-05-09PCVX31.130.360.1011810
2025-05-12PCVX31.60.360.1911750
2025-05-13PCVX30.060.3655.0511753
2025-05-14PCVX29.390.440.0210544
2025-05-15PCVX30.920.630.488163
2025-05-16PCVX31.830.6249.298191
2025-05-19PCVX32.010.431.836127
2025-05-20PCVX36.620.440.366238
2025-05-21PCVX33.940.420.506483
2025-05-22PCVX33.940.420.656506
2025-05-23PCVX32.580.420.146528
2025-05-27PCVX31.690.4211.576525
2025-05-28PCVX31.360.440.506609
2025-05-29PCVX32.770.440.106614
2025-05-30PCVX32.50.440.676628
2025-06-02PCVX35.010.440.106638
2025-06-03PCVX34.650.442.536657
2025-06-04PCVX33.860.440.156677
2025-06-05PCVX34.640.450.206682
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07PCVX29.00-14.6- -4.40
2025-05-08PCVX31.43-14.6- -4.40
2025-05-09PCVX31.15-14.6- -4.65
2025-05-12PCVX31.59-14.6- -4.65
2025-05-13PCVX30.05-5.8- -4.69
2025-05-14PCVX29.40-5.8- -4.69
2025-05-15PCVX30.91-5.8- -4.69
2025-05-16PCVX31.86-5.8- -4.69
2025-05-19PCVX32.03-5.8- -4.69
2025-05-20PCVX36.57-5.8- -4.69
2025-05-21PCVX33.97-5.8- -4.69
2025-05-22PCVX33.97-5.8- -4.69
2025-05-23PCVX32.57-5.8- -4.69
2025-05-27PCVX31.73-5.8- -4.69
2025-05-28PCVX31.36-5.8- -4.69
2025-05-29PCVX32.79-5.8- -4.69
2025-05-30PCVX32.49-5.8- -4.69
2025-06-02PCVX35.02-5.8- -4.69
2025-06-03PCVX34.65-5.8- -4.69
2025-06-04PCVX33.87-5.8- -4.69
2025-06-05PCVX34.80-5.8- -4.69
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07PCVX-2.840.419.85
2025-05-08PCVX-2.840.419.85
2025-05-09PCVX-2.780.419.85
2025-05-12PCVX-2.780.049.62
2025-05-13PCVX-2.780.049.62
2025-05-14PCVX-2.780.049.62
2025-05-15PCVX-2.780.049.62
2025-05-16PCVX-2.780.049.62
2025-05-19PCVX-2.781.799.63
2025-05-20PCVX-2.471.799.63
2025-05-21PCVX-2.471.799.63
2025-05-22PCVX-2.471.799.63
2025-05-23PCVX-2.471.799.63
2025-05-27PCVX-2.475.699.63
2025-05-28PCVX-2.475.6910.79
2025-05-29PCVX-2.475.6910.79
2025-05-30PCVX-2.475.6910.79
2025-06-02PCVX-2.476.1910.79
2025-06-03PCVX-2.476.1910.79
2025-06-04PCVX-1.916.1910.79
2025-06-05PCVX-1.916.1910.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.04

Avg. EPS Est. Current Quarter

-1.16

Avg. EPS Est. Next Quarter

-1.21

Insider Transactions

-1.91

Institutional Transactions

6.19

Beta

1.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

20

Sentiment Score

35

Actual DrawDown %

71.3

Max Drawdown 5-Year %

Target Price

125.75

P/E

Forward P/E

PEG

P/S

P/B

1.4

P/Free Cash Flow

EPS

-4.07

Average EPS Est. Cur. Y​

-4.69

EPS Next Y. (Est.)

-5.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.44

Return on Equity vs Sector %

-39.9

Return on Equity vs Industry %

-22.1

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.41

EBIT Estimation

Vaxcyte, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 414
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today
news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance
stock history PCVX – Vaxcyte, Inc. invest stock market
stock prices PCVX premarket after hours
ticker PCVX fair value insiders trading